Generic competition has eroded sales of multiple sclerosis drug Ampyra, marketed as Fampyra outside the U.S. Biogen told Acorda Therapeutics that it’s terminating its ex-U.S. rights to Fampyra in order to focus on other priorities, which include expanding beyond MS.
In an open letter published by BIO, the executives emphasized the importance of science-driven evaluation of medicines and regulatory independence. The letter came amid growing concern about political pressure over the FDA, as well as lack of diversity in trials and companies being too quick to announce data that are inconclusive.
Discover the top AI-powered EAP providers for 2026. Compare platforms like Kyan Health and Spring Health on triage speed, global reach, and clinical quality to transform workforce wellbeing.
More than 150 people - including biotechnology and investment executives and academics - have signed a letter warning that actions dismissals of Chinese scientists create a hostile climate that threatens U.S. leadership in biomedical science.
It’s an incredible time for the life sciences, panelists at a Biotech Showcase session on Monday agreed. However, it comes with a catch: The greater the miracle, the greater the anguish when a patient can’t afford or can’t access the drug.
Janelle R. Anderson, PhD, Managing Partner of CTI Life Sciences Fund, has started a new podcast in which she interviews business leaders within the life sciences and venture capital.
Central nervous system therapies company Neuronex is being acquired by Acorda Therapeutics (NASDAQ:ACOR) in a deal valued at up to $133 million, yielding to Acorda a novel epilepsy treatment nearly ready for filing with the U.S. Food and Drug Administration. But privately held Neuronex gets just $2 million up front. Critical to the Morrisville, North […]
By reducing administrative burden and redesigning workflows around human needs, it creates space for what matters most: connection between clinicians and patients.